Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Kingswood Investments","pharmaFlowCategory":"D","amount":"$8.9 million","upfrontCash":"Undisclosed","newsHeadline":"MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial Public Offering and Nasdaq Listing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Kingswood Investments","pharmaFlowCategory":"D","amount":"$8.9 million","upfrontCash":"Undisclosed","newsHeadline":"MIRA Pharmaceuticals, Inc. Announces Closing of $8.9 Million Initial Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"MZ Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Mira Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Pharmaseed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MIRA Pharmaceuticals Announces Collaboration with Pharmaseed","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Frontage Laboratories, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Mira Pharmaceuticals

    Menu

    Mira Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Mira Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission

              Details:

              Ketamir-2 is a novel oral ketamine analog which could potentially deliver ultra-rapid antidepressant effects by inhibiting NMDA receptor. It is being evaluated for the treatment of major depressive disorder with suicidal ideation & treatment-resistant depression.

              Lead Product(s): Ketamine Hydrochloride

              Therapeutic Area: Psychiatry/Psychology Product Name: Ketamir-2

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Frontage Laboratories, Inc

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 02, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mira Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MIRA Pharmaceuticals Announces Collaboration with Pharmaseed

              Details:

              The collaboration aims to assist MIRA in the research and development of Ketamir-2 (ketamir analog), which aids individuals struggling with major depressive disorder with suicidal ideation.

              Lead Product(s): Ketamine Analog

              Therapeutic Area: Psychiatry/Psychology Product Name: Ketamir-2

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: Pharmaseed

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 08, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mira Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2

              Details:

              Under the agreement, MIRA will have the exclusive right in the U.S., Canada, and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analog designed to revolutionize the landscape of depressive disorder treatments.

              Lead Product(s): Ketamine Analog

              Therapeutic Area: Psychiatry/Psychology Product Name: Ketamir-2

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: Miralogx

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mira Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts

              Details:

              The collaboration aims to enhance MIRA's visibility within the investment community and spotlight the potential of its drug candidate, MIRA1a (synthetic tetrahydrocannabinol analog), in treating anxiety, cognitive decline, and neuropathic pain.

              Lead Product(s): Synthetic Tetrahydrocannabinol Analog

              Therapeutic Area: Psychiatry/Psychology Product Name: MIRA1a

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: MZ Group

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration September 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mira Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MIRA Pharmaceuticals, Inc. Announces Closing of $8.9 Million Initial Public Offering

              Details:

              The company expects to use the net proceeds to advance its clinical development programs, including MIRA1a (synthetic tetrahydrocannabinol analog), being developed as the first prescription drug to target the CB1 and CB2 receptors for chronic pain and anxiety.

              Lead Product(s): Tetrahydrocannabinol Analog,Cannabidiol

              Therapeutic Area: Psychiatry/Psychology Product Name: MIRA1A

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Kingswood Investments

              Deal Size: $8.9 million Upfront Cash: Undisclosed

              Deal Type: Public Offering August 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mira Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial Public Offering and Nasdaq Listing

              Details:

              The company expects to use the net proceeds to advance its clinical development programs, including MIRA1a (synthetic tetrahydrocannabinol analog), being developed as the first prescription drug to target the CB1 and CB2 receptors for chronic pain and anxiety.

              Lead Product(s): Synthetic Tetrahydrocannabinol Analog

              Therapeutic Area: Psychiatry/Psychology Product Name: MIRA1a

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Kingswood Investments

              Deal Size: $8.9 million Upfront Cash: Undisclosed

              Deal Type: Public Offering August 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY